Home > Inhibitors & Agonists > Ras-Raf-MAPK-ERK
Cat. No. Product name CAS No.
DC7736 6H05

6H05 is a selective, and allosteric inhibitor of oncogenic K-Ras(G12C).

1469338-01-9
DC11622 MAP3K14-IN-173

A novel potent MAP3K14 kinase inhibitor with IC50 of 1.8 nM (NIK autophosphorylation).

2113617-02-8
DC11610 AKS1-IN-19

A novel potent, selective and orally active ASK1 (MAP3K5) inhibitor with pIC50 of 8.3.

2089638-10-6
DC11959 PD 184161

A potent, orally-active MEK1/2 inhibitor with IC50 of 10-100 nM.

212631-67-9
DC11558 DLK-IN-14

A potent, selective, CNS penetrant dual leucine zipper kinase (DLK, MAP3K12) inhibitor with Ki of 3 nM.

1620574-24-4
DC10417 Acumapimod

Acumapimod (BCT197) is an orally active p38 MAP kinase inhibitor, with an IC50 of less than 1 μM for p38α.

836683-15-9
DC10048 APS-2-79

APS-2-79 is a novel modulator of KSR-dependent MAPK signalling,KSR2,IC50=120 nM

2002381-25-9
DC9808 APS-2-79 hydrochloride

APS-2-79 is a novel modulator of KSR-dependent MAPK signalling,KSR2,IC50=120 nM

2002381-31-7
DC10738 ARS-1323

ARS-1323 is a novel inhibitor of mutant K-ras G12C.

1698024-73-5
DC10725 ARS-1620

ARS-1620 is a covalent compound with high potency and selectivity for KRAS-G12C.

1698055-85-4
DC12031 ARS-1630

ARS-1630 is the R-conformational atropisomer of ARS-1620, 1,000-fold less potent than ARS-1620 (1.2 ± 0.6 M-1s-1) and thus acts as a unique inactive control compound..

1698055-86-5
DC8816 ARS-853

ARS-853 is a selective, covalent inhibitor of KRAS-G12C that inhibits mutant KRAS driven signaling by binding to the GDP bound oncoprotein and preventing activation.

1629268-00-3
DC10781 ASK1-IN-1

ASK1-IN-1 is an apoptosis signal regulating kinase 1 (ASK1) inhibitor extracted from patent WO2016025474A1, Compound 4.

1262041-49-5
DC10649 AX15836

AX15836 is a highly potent and selective ERK5 inhibitor.

2035509-96-5
DC12376 AZ304

AZ304 is a novel potent, dual BRAF inhibitor targeting the kinase domains of wild type BRAF, V600E mutant BRAF and wild type CRAF with IC50 of 79 nM, 38 nM and 68 nM, respectively.

942507-42-8
DC10985 AZ6197

AZ6197 (AZ-6197) is a potent, selective, reversible inhibitor of ERK1/2 with IC50 of <0.3 nM (ERK2), inhibits pERK/pRSK with IC50 of 12/62 nM in A375 cells, respectively.

2023003-94-1
DC11481 AZD-0364

AZD-0364 is a potent and selective ERK2 inhibitor extracted from patent WO2017080979A1, compound example 18, has an IC50 of 0.6 nM.

2097416-76-5
DC1069 AZD6244 (Selumetinib,ARRY-142886)

AZD6244 (Selumetinib, ARRY-142886) is highly potent to inhibit MEK1 with IC50 of 14 nM.

606143-52-6
DC7077 AZD8330(ARRY-424704; ARRY-704)

AZD8330(ARRY-424704; ARRY-704) is a novel, selective, non-ATP competitive MEK 1/2 inhibitor with IC50 of 7 nM.

869357-68-6
DC10994 Balamapimod

Balamapimod (MKI-833) is an orally active, reversible Ras/Raf/MEK inhibitor developed for antineoplastic potential..

863029-99-6
DC12278 Belvarafenib

Belvarafenib is a potent and pan RAF (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC50s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively.

1446113-23-0
DC7107 BI-78D3

BI-78D3 is a competitive c-Jun N-terminal kinase (JNK) inhibitor (IC50 = 280 nM) that displays > 100 fold selectivity over p38α and no activity at mTOR and PI-3K.

883065-90-5
Page 1 / Total 6 FirstPrevNextLastGoto